Content Conference Coverage Conferences EASL 2014
EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B
- Details
- Category: HBV Treatment
- Created on Friday, 02 May 2014 00:00
Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.
EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients
- Details
- Category: HBV Treatment
- Created on Monday, 14 April 2014 00:00
Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in HBeAg positive chronic hepatitis B patients, as did added interferon after long-term nucleoside therapy, but adding interferon after a only short course of antivirals did not improve response, according to a set of studies presented at the 49th EASL International Liver Congress last week in London.
EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission
- Details
- Category: HBV Vaccines
- Created on Tuesday, 29 April 2014 00:00
An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the EASL International Liver Congress this month in London.
EASL 2014: International Liver Congress Starts this Week in London
- Details
- Category: HBV Treatment
- Created on Wednesday, 09 April 2014 00:00
The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.
EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- Details
- Category: Liver Cancer/HCC
- Created on Monday, 14 April 2014 00:00
Dramatic regional differences in survival rates for people with hepatocellular carcinoma (HCC) are largely attributable to varying national policies regarding screening and treatment, according to study findings presented at the 49thEASL International Liver Congress last week in London. Related research showed that percutaneous radiofrequency ablation is effective for treating single liver cancer tumors.
More Articles...
- EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- CROI 2014 & EASL 2014: Treating Hepatitis B and C in HIV+ People Reduces Liver Disease
- EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant
- EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study
- EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients
- EASL 2014: Kaiser Study Examines Who Receives Hepatitis C Treatment
- EASL 2014: Researchers Look at Treatment as Prevention for Hepatitis C
- Coverage of the 2014 EASL International Liver Congress
- Coverage of the 2014 EASL International Liver Congress
- EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4
- EASL 2014: Sofosbuvir Works Well Despite Multiple Negative Predictive Factors
- AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence
- EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6
- EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates
- EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% of Previously Untreated HCV Genotype 4
- EASL 2014: BMS Dual Combo Cures 90% of Genotype 1b Hepatitis C in 24 Weeks
- EASL 2014: Sofosbuvir + Ribavirin Safe and Effective for Hepatitis C Patients with Advanced Liver Disease
- EASL 2014: AbbVie 3-drug Combination Cures Up to 96% of Hepatitis C Patients with Cirrhosis
- EASL 2014: Sofosbuvir + Simeprevir Shows High Cure Rates for Hep C Patients with or without Cirrhosis
- EASL 2014: Sofosbuvir + Ledipasvir Cures More than 90% of First-time and Retreated Genotype 1 Patients
- EASL 2014: AbbVie Oral Regimen Cures 96% of Treatment-experienced Genotype 1 Patients
- EASL 2014: Sofosbuvir + Ledipasvir Is Safe and Effective for Relapsers and Hard-to-Treat Hep C Patients
- EASL 2014: 88% of Previous Relapsers Cured with Simeprevir Triple Therapy
- EASL 2014: Sofosbuvir + Ledipasvir Produces Early Cure for 100% of HIV/HCV Coinfected Patients
- EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs
- EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- EASL 2014: Chinese Herbal Compound Inhibits Hepatitis C Virus Replication
- Studies Shed Light on Hepatitis C Virus Sexual Transmission among Gay Men
- EASL 2014: Obeticholic Acid Looks Promising for Primary Biliary Cirrhosis, May Improve Gut Health
- EASL 2014: Fatty Liver Disease Is a Risk Factor for Heart Disease and Diabetes
- DDW 2014 and EASL 2014: Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Web Design and Development by